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EXPERIMENTAL PRODUCTION OF GYNECOMASTIA WITH
CHORIONIC GONADOTROPIN*
GERALD KLATSKINt AND PAUL L. MUNSONt
The male mammary glands often undergo hyperplasia in the presence of
tumors associated with a high urinary excretion of chorionic gonadotropin.
Included in this group are the chorioepitheliomas, both testiculari'3 and
extragenital,"" and, more rarely, teratomas"' and seminomas""' of the
testis. Although the histological and clinical features differ in each of these
tumors, there is reason to believe that all contain chorionic elements when
accompanied by chorionic gonadotropin in the urine."2
Less commonly gynecomastia occurs in association with non-choriogenic
tumors of the testis. These comprise a heterogeneous group with respect to
their hormonal excretion patterns, but in general fall into one of two cate-
gories: (i) those in which the gynecomastia is probably a non-specific effect
related to loss of testicular tissue by tumor invasion, radiation therapy, or
surgical extirpation,' and in which the excretion of androgen is low and of
follicle-stimulating gonadotropic hormone (FSH) high,' and (ii) those in
which the gynecomastia appears to be more directly related to hormonal
stimulation by the tumor itself, as in Sertoli-cell'0 and aberrant adreno-
cortical'1 tumors. In these the excretion of estrogen is increased, and since
removal of the tumor results in both a reduction in urinary estrogen and a
regression in the gynecomastia, it is highly probable that the tumor is the
source of the estrogen and that the latter is an important factor in stimulat-
ing mammary growth. Gynecomastia has also been reported as a rare com-
plication in interstitial- or Leydig-cell tumors,"' but the histological
diagnosis in such cases has been questioned.' As a rule these tumors pro-
duce virilization in children, but exert no hormonal effects in adults.3' On
the basis of a study of dog tumors, Huggins and Moulder' have presented
evidence to show that those testicular tumors associated with gynecomastia
and previously reported as interstitial-cell tumors were probably incorrectly
interpreted examples of Sertoli-cell tumors. However, in one of these cases,
that of Hunt and Budd," the possibility of chorionic elements in the tumor
does not appear to have been completely excluded, since the urine contained
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a large amount of luteinizing gonadotropin, presumably of the chorionic
type.
The contributions of Hamburger and his associates7' '9 have shed con-
siderable light on the relationships between testicular tumors and the
urinary gonadotropins. These investigators were the first to point out the
necessity for distinguishing between the excretion of luteinizing chorionic
gonadotropin derived from certain types of testicular tumor tissue, and the
excretion of follicle-stimulating gonadotropin originating in the anterior
lobe of the pituitary in response to a decrease in androgen secretion, related
to non-specific testicular injury. They clearly demonstrated that only in the
case of the choriogenic tumors is extirpation followed by a decrease in
gonadotropin excretion. Moreover, they attempted to correlate the type of
gonadotropin excreted with the histological features and clinical course of
the tumors they studied, and concluded that the excretion of chorionic
gonadotropin was characteristic of radioresistant, mixed epitheliomas, a
group of tumors including chorioepitheliomas and embryonal adenocarci-
nomas,27 and that it denoted a bad prognosis, while the excretion of FSH in
increased amounts was characteristic of radiosensitive seminomas and indi-
cative of a more favorable outlook. Further studies by FuruhjelmM and
Twombly27 have confirmed the different sites of origin and significance of
the two types of gonadotropin, but have not corroborated the close correla-
tion between the type of gonadotropin present in the urine and the histo-
logical features of the tumor reported by Hamburger. However, it is well
recognized that the structure of the testicular tumors, and especially of
their metastases, is often not uniform, and it is highly probable that
chorionic elements are always present when the urine contains chorionic
gonadotropin.1'27
Ever since Cooke2 first called attention to the occurrence of gynecomastia
in chorioepithelioma in 1915, the subject of its pathogenesis has been a
matter of speculation and debate. Unfortunately, not even the great strides
made in endocrinology since then have added materially to Cooke's original
hypothesis that the gynecomastia is probably the result of stimulation by a
substance present both in chorioepitheliomatous tissue and the normal
placenta. It is now known, of course, that several analogous, if not identical,
hormones can be isolated from each of these tissues, but whether, in the case
of testicular chorioepithelioma, any one of these hormones stimulates the
mammary gland directly or exerts its effects indirectly by activating other
endocrine glands, is still unknown. It is reasonably certain, however, from
cases like Warthin's,"7 in which the gynecomastia subsided after the tumor
had been removed and recurred when metastases made their appearance,
and from cases of extragenital chorioepithelioma with gynecomastia,`42
that the gynecomastia is related to the humoral activity of the tumor and
not to the coincidental testicular atrophy which is often present.
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Most authors' '- ' ascribe the gynecomastia to a direct estrogen effect,
and certainly the frequency with which hyperestrinuria has been demon-
strated" 17-I ahd the similarity between the type of mammary duct hyper-
plasia found in chorioepithelioma and that produced by estrogen' appear to
support this hypothesis. However, there is no unanimity of opinion regard-
ing the origin of this estrogen. Many'9' ' consider it to be a secretory
product of the tumor itself because of the high estrogen levels found in some
chorioepitheliomas.' 8 Others regard the testis as the source of estrogen,
basing this opinion on the experiments of Geschickter and his associates,'
who showed that chorionic gonadotropin derived from pregnancy urine
produced mammary growth in intact male monkeys, but not in castrates,
and on the frequent occurrence of interstitial-cell hyperplasia in the unaf-
fected testis in chorioepithelioma.-'19-b'- While the testis may play a r6le in
the pathogenesis of gynecomastia in chorioepithelioma, the hyperplastic
interstitial cells can hardly be taken as evidence of increased estrogen pro-
duction in the light of present knowledge concerning their androgen-
producing function. Finally, it has been suggested1"' that the adrenal cortex
may be the source of estrogen under the influence of chorionic gonadotropin
stimulation. Certainly there is evidence that some adrenocortical derivatives
are estrogenic,' and that the adrenal cortex may be stimulated by chorionic
gonadotropin.' Moreover, Ferguson' has reported the occurrence of swell-
ing and hyperemia of the adrenals in cases of teratoma of the testis with
elevated urinary gonadotropins. However, this has not been found with any
degree of regularity," 2' 4' 9, 11, 14' 15, M,2nor can the possibility be excluded that
the adrenocortical hyperplasia in such cases is the result rather than the
cause of hyperestrinemia, an effect well recognized in animals.""'
The pituitary is enlarged in many cases of chorioepithelioma and shows
changes in the cellular pattern of its anterior lobe resembling those of
pregnancy.'8'5 " 8 10-13 16, W" This has led Gilbert' and others to suggest that
the development of gynecomastia may be a pituitary effect. Although this
hypothesis is consistent with the mammogen theory of breast development
once held by Turner and his associates," more recent work4'" indicates
that the pituitary may exert a potentiating or sensitizing effect, but that it
does not promote mammary growth directly.
In a significant number of chorioepitheliomas the mammary glands go on
to alveolar development5"0" and the secretion of a colostrum-like mate-
rial,2'" StIfeatures not seen ordinarily after estrogen administration, but
highly suggestive of a progesterone effect. The possibility that progesterone
may be implicated has been considered, and, indeed, pregnandiol has been
recovered from the urine in several instances.13'l9 However, it is unlikely
that progesterone is the primary factor, since, except in the mouse,6 it does
not produce proliferation of the duct system.w0
It is obvious from the preceding discussion that the pathogenesis of
choriogenic gynecomastia is still far from well understood, and that further
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hormone assays and morphological studies of the endocrine system in such
cases are not likely to add materially to what is already known. Only the
experimental approach appears to offer any hope of solving this problem,
and since the response of the mammary gland to hormonal stimuli varies
in different species it would be highly desirable to conduct these studies in
man. Recently we were afforded an opportunity to carry out such experi-
ments and these are the subject of the present report. They were under-
taken following the chance observation, made during the course of some
studies of endocrine function in a patient with Laennec's cirrhosis, that
massive doses of chorionic gonadotropin produced gynecomastia. Similar
effects were observed in a second case of cirrhosis and in two carefully
selected controls, one with marked congenital atrophy or aplasia of the
testis, and the other with marked pituitary deficiency, but not in two other
subjects. Parallel studies of hormone excretion and of the histological
changes in the testes and mammary glands were carried out. While the
results of these experiments fail to elucidate the pathogenesis of choriogenic
gynecomastia, they do clarify several disputed issues, and, more important,
point the way for further similar studies.
ExPERIMENTAL SUBJECTS
Seven subjects were studied in the manner to be described-six males
and a female control. Cases 1 and 2 were young cirrhotics who develope4
gynecomastia following the administration of chorionic gonadotropin. Case
3, a young cirrhotic who also had congenital ( ?) testicular atrophy, was
selected for study to determine whether the testes were essential for this
action of chorionic gonadotropin. Since gynecomastia failed to develop in
this subject, case 4, a young man with congenital ( ?) atrophy or aplasia of
the testes but without evidence of liver disease, was investigated as a con-
trol for case 3, and also to determine whether the presence of liver disease
was essential for the mammary effect of chorionic gonadotropin. Case 5, a
young man with severe pituitary deficiency, was selected for study to deter-
mine whether the effects of chorionic gonadotropin were mediated through
the pituitary. Case 6 was a presumably normal male control with respect to
his endocrine system and liver; however, biopsy of the testis revealed some
degree of hypoplasia. Case 7 was a middle-aged female with cirrhosis who
served as a control for the hormone excretion studies in the six male
subjects investigated.
Case 1. Laennec's cirrhosis. E.R., V-47 149, a 32-year-old white, married male, had
a history of chronic alcoholism and poor diet for an indeterminate number of years.
Cirrhosis was discovered three years before the present study, following an hema-
temesis. Hematemesis recurred a year later and again shortly before admission to the
hospital. Loss of libido had been noted for six to eight months.
The patient was well developed and exhibited no sigIns of malnutritioni. There were
several large spider nevi, but no icterus, ascites, edema, or visible portal venous col-
477YALE JOURNAL OF BIOLOGY AND MEDICINE
lateral circulation. Both the liver and spleen were moderately enlarged and firm. The
testes were soft but were not decreased in size. The penis and prostate were normal in
size and there was a normal distribution of hair.
Biopsy of the liver revealed an extensive cirrhosis with marked fatty infiltration, and
chemical studies indicated moderate impairment of function (Table 1). Esophageal
varices could not be demonstrated by x-ray. There was moderate anemia due to
hemorrhage, but this was promptly corrected by transfusion.
Case 2. Laenntec's cirrhosis. V.V., V-47 343, a 38-year-old, white, single male, had a
history of chronic alcoholism and a poor diet for six years. He was admitted to the
hospital because of jaundice and recurrent epistaxis of one month's duration. There
was a history suggestive of an attack of infectious hepatitis six years earlier. No loss
of libido had been noted.
The patient was well developed and exhibited moderate obesity, slight icterus,
numerous spider nevi, and marked hepatosplenomegaly, but no ascites, edema, testicular
atrophy, or loss of hair.
Biopsy of the liver revealed severe cirrhosis with marked fatty infiltration, and liver
function was markedly impaired (Table 1). No esophageal varices could be demon-
strated by x-ray.
Case 3. Laennec's cirrhosis and congenital (P) testicular atrophy. J.M., N-B 79 312,
a 37-year-old white, single male, was admitted to the hospital because of anemia,
anorexia, weight loss, and dyspnea of several months' duration. Alcohol consumption
had been high and the diet inadequate for an indeterminate period. The testes and
penis had been very small since childhood, but the patient claimed that libido and
potency had been normal until one year previously when both were lost. There was a
history of mumps in childhood, but none of orchitis or testicular injury.
The patient looked chronically ill and exhibited marked pallor, slight icterus, and
signs of moderate malnutrition. A small amount of ascitic fluid was present, but there
were no signs of portal collateral circulation, edema, or spider nevi. The liver and
spleen were moderately enlarged and firm. The penis and scrotum were markedly
underdeveloped, and the testes were very small and soft. The prostate was small and
firm. The voice was rather high-pitched and the general configuration of the body was
feminine, but the pubic and axillary hair distribution was that of a normal adult male.
Biopsy of the liver revealed a severe cirrhosis with marked hemosiderosis and fatty
infiltration, and chemical studies indicated moderate impairment of function (Table 1).
Hematological studies revealed a moderately severe macrocytic hyperchromic anemia,
but the gastric juice contained free HCl, the bone marrow showed normoblastic hyper-
plasia, and there was no increase in erythrocyte fragility. A glucose tolerance test was
normal. Neither the nature of the anemia nor the significance of the hemosiderosis was
adequately explained, although the former improved following transfusions and
improvement in the diet.
Case 4. Congenital (f) atrophy or aplasia of the testes. W.S., V-47 981, a 34-year-
old married, white male, was admitted to the hospital for treatment of a peptic ulcer
of two years' duration. The testes had always been very small, but physical and sexual
development had been normal in other respects. The patient began to shave at the age
of seventeen and regarded his libido and potency as normal. He had been married for
four years and enjoyed a normal sex life, although he had proved to be sterile.
There was no history of mumps orchitis, testicular injury, or serious illness in the past.
There had been a weight gain of 70 pounds in the preceding seven years.
The patient was a tall, muscular, somewhat obese young man who measured six feet
in height and weighed 200 pounds. There was a heavy beard and a moderate growth
of hair in the axillary and pubic areas and over the trunk. The voice was moderately
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deep and the penis appeared normal, measuring 8 cm. in length, but the scrotum was
unusually small and contained 2 small ovoid masses measuring 2 x 1 x 1 cm. each.
These were assumed to be testes, but on two occasions when they were biopsied only
epididymal tissue was obtained. The biopsies were carried out on opposite sides by two
different surgeons, the second being a urological specialist who was aware of the previ-
ous failure to obtain testicular tissue. It is highly probable, therefore, that there was
little or no testicular tissue present. In keeping with this assumption was the observa-
tion that a sample of semen contained no spermatozoa. The prostate appeared to be of
normal size. The remainder of the examination revealed no other abnormalities.
Laboratory studies, including tests of liver function, were all within normal limits,
except for the results of the urinary hormone assays which will be discussed elsewhere.
It was difficult to classify the nature of the testicular disorder in this case since the
entire scrotal contents were not available for study, but in many ways it appeared
unique. In some respects it was reminiscent of the prepubertal functional castration
described by Heller, Nelson, and Roth,5' but the absence of overt eunuchoidism
appeared to exclude this possibility. Similarly, the syndromes of Klinefelter52 and
del CostilloTM were considered, but the complete lack of testicular elements did not
appear compatible. Conceivably this was an example of testicular aplasia with main-
tenance of the secondary sex characters by the adrenal cortex, as has been described in
rare cases of castration.'
Case 5. Pituitary deficiency. J.R., V-48 935, a 37-year-old single, white male, was
admitted to the hospital because of attacks of headache and vomiting of several months'
duration. One and one-half years previously he had suffered an attack of meningitis,
and immediately following had developed typical symptoms of myxedema, loss of facial
and body hair, and marked atrophy of the testes associated with complete loss of
libido and potency. There was a history of chancre seven years previously, presumably
cured following a six months' course of therapy.
The patient exhibited typical signs of severe myxedema. Facial and body hair was
very sparse. The skin was coarse, pale and dry and had a fawn-colored pigmentation
over the face. The testes were very small and soft and were associated with marked
atrophy of the penis and prostate. The fundi, visual fields, and neurological examina-
tion revealed nothing of note. The blood pressure was low at all times, ranging between
80/52 and 98/64.
The basal metabolic rate and the serum precipitable iodine were low, the former
ranging between -24 and -30 per cent, the latter between 4.1 and 2.7 gamma per cent.
The results of the Kepler-Power test were equivocal with respect to adrenal function,
but there was no fall in eosinophils following an injection of epinephrine. A single
injection of ACTH failed to lower the eosinophil count in four hours, but multiple
doses lowered the count slightly in 24 hours. The blood sugar and serum electrolytes
were within normal limits. Intravenous glucose and insulin tolerance tests were like-
wise normal. X-rays of the skull revealed no abnormalities. X-ray of the chest showed
the presence of calcified tubercles and hilar nodes. A tuberculin test (P.P.D. first
strength) was positive. A histoplasmin skin test was also positive, but the complement
fixation test for histoplasmosis was negative. Serological tests for syphilis were nega-
tive. The spinal fluid was not examined at this time, but subsequently showed a nega-
tive serological test for syphilis; cultures for bacteria and fungi, guinea-pig studies
for tubercle bacilli, and inoculation of animals and eggs for viruses all failed to
demonstrate any organisms.
There seems to be little doubt that this patient had pituitary deficiency manifested by
myxedema, depressed gonadal function, and possibly mild Addison's disease. However,
the nature of the pituitary lesion was not determined. The possibility of a tuberculoma
was seriously considered, especially when the patient developed a second attack ofEXPERIMENTAL PRODIJCTION OF GYNECOMASTIA
meningitis some time after these studies were completed. Since then his symptoms have
been relieved by substitution therapy with thyroid extract and testosterone proprionate,
but the diagnosis still remains in doubt.
Case 6. "Normal" male control. S.P., V-54 558, a 39-year-old white male, had been
hospitalized for eight months because of multiple sclerosis of three years' duration at
the time of these studies.
He was in a good state of nutrition and had a heavy beard and deep masculine voice.
The external genitalia were above average in size, the testes measuring 4.3 x 2.2 x 2.7
and 4.7 x 2.4 x 2.9 cm. respectively. The remainder of the physical examination
revealed no abnormalities other than signs of advanced multiple sclerosis.
Routine laboratory studies, including tests of liver function, yielded normal results.
Case 7. Female cirrhotic control. T.F., N-C 21 233, a 43-year-old white housewife,
was admitted to the hospital because of ascites and jaundice of several weeks' duration.
There was a history of alcoholism and poor diet for 15 years. A left oophorectomy had
been performed at the age of 14, but the menstrual cycles had continued regularly until
14 months previously when they ceased abruptly.
The patient was moderately obese and did not appear ill. There was moderate icterus
of the skin. One spider nevus was present on the neck. The liver was greatly enlarged
and firm and was associated with moderate ascites and visible portal venous collateral
circulation. The spleen, however, was not palpable. The ankles were moderately
edematous.
Liver biopsy revealed moderately severe cirrhosis with marked fatty infiltration, and
chemical studies indicated moderately severe impairment of liver function (Table 1).
There was amoderate macrocytic anemia. No esophageal varices could be demonstrated
by x-ray.
METHODS
Chorionic gonadotropin administration. The preparation used ("A.P.L.," Ayerst,
McKenna and Harrison, Limited*) was administered intramuscularly as indicated in
Table 2. This material is extracted from human pregnancy urine by the method of
Collip' and is said to consist almost exclusively of luteinizing gonadotropin, although
negligible traces of FSH and prolactin may be present; the method of extraction is
thought to preclude the presence of steroids.'
Liver function tests. The methods used in this laboratory have been described
elsewhere.'
Urinary hormone assays. Twenty-four or 48-hour specimens of urine were obtained
from the patients with special precautions to insure completeness of collection. No
preservative was added, but the urine was kept refrigerated and processed within 24
hours after completion of the collection.
A full or half 24-hour specimen was extracted for assay of 17-ketosteroids, andro-
gens, estrogens, and "estroids," as described by Salter, Humm, and Oesterling.'8
17-ketosteroids were estimated in the crude neutral steroid extract by the method of
Cahen and Salter.' Range of values for normal males 10 to 25 mg. per day, and for
non-pregnant females 6 to 20 mg.
Androgen excretion was determined in aliquots of the crude neutral fraction by the
bioassay method of Rakoff, Paschkis, and Cantarow.' Range of values for normal
* The authors are indebted to Dr. S. H. Jaros, Medical and Research Division,
Ayerst, McKenna and Harrison, Limited, New York, New York, for generous supplies
of the "A.P.L." used in this investigation.
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males, 2 to 10 mg. of androsterone equivalent (20 to 100 international units of andro-
gen) per day, and for non-pregnant females, 1 to 10 mg. of androsterone equivalent.
"Estroids" were determined colorimetrically by the modified Kober procedure
described by Salter and his associates,',
' using a purified phenolic fraction. Range
of values for normal males, 20 to 80 micrograms of estrone equivalent per day and
for non-pregnant females, 40 to 120 micrograms.
Estrogen excretion was also estimated biologically in the crude phenolic fraction by
a modification of the Marrian and Parkes and Mather methods, as described by Humm,
Munson and Salter."1 Range of values for normal males 0.5 to 3.0 micrograms of
TABLE 2
RELATIONSHIP BETWEEN CHORIONIc GONADOTROPIN ADMINISTRATION AND
DEVELOPMENT OF GYNECOMASTIA
Gonadotropin adnministered __
Daily Total
Case dose Days Dose Sid
units units
1 2,000 70 140,000 Left
2 2,000 80 160,000 Left
Gynecomastia
Appearance time MIaximum
{e Days Gonadotropin
units
34 68,000
size
cm.
2.5
29 58,000 2.5
3 4,000 40 160,000 None
4 2,143* 95 195,000 Left 53 115,000 4.0
Right 95 195,000 4.0
5 4,000 45
10,000 34
6 5,000 10
10,000 19
Right 43 172,000 2.5
510,000 Left 56 290,000 2.0
240,000 None
7 2,000 30t 60,000 Female control: no change in breasts
* 5,000 units 3 times a week.
tperiod of administration 32 days.
estrone equivalent (5 to 30 international units of estrogen) per day, and for non-
pregnant females 1 to 6 micrograms of estrone equivalent.
It is recognized that the short period of acid hydrolysis of urine (7 minutes), which
was chosen because it is desirable for the liberation of the neutral steroids from their
conjugates, may have been inadequate to obtain a quantitative yield of the estrogens.
It is assumed, nevertheless, that the estrogen values reported are valid for comparative
purposes.
Gonadotropin (FSH) excretion was estimated by the method of Varney and Koch,'
usually on a full 24-hour specimen of urine. Range of values for normal males, 10 to 40
mouse uterine units per day and for non-pregnant females, 10 to 50 mouse uterine
units.
The normal values cited are based on the experiences of this laboratory. However,
it should be emphasized that the values for women are based on more limited experi-
ence than those for men, and that a minority of subjects of both sexes yield data
somewhat outside the ranges given.
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RESULTS
Mamtnmary glands. Four of the six male subjects who were given
chorionic gonadotropin developed typical gynecomastia (Table 2). These
included two of the three patients with Laennec's cirrhosis (cases 1 and
2), the patient with congenital ( ?) atrophy or aplasia of the testes (case 4),
and the patient with pituitary deficiency (case 5). Only the cirrhotic with
congenital ( ?) atrophy of the testis (case 3) and the "normal" male control
(case 6) failed to develop gynecomastia.
The first sign of gynecomastia appeared on the 29th to 53d day of
gonadotropin therapy, or following the administration of a total dose of
58,000 to 172,000 international units. It is of interest that the gynecomastia
was bilateral in only two of the four subjects (cases 4 and 5), and that in
each instance the second mammary gland took considerably longer to
undergo hyperplasia than the first, not appearing until the 95th and 56th
day of treatment respectively, or following the administration of 195,000
and 290,000 international units. Since cases 1 and 2 received only 68,000
and 58,000 international units, respectively, it is highly probable that they
too would have developed bilateral gynecomastia had gonadotropin therapy
been continued longer. Similarly, the failure of gynecomastia to develop at
all in cases 3 and 6 can probably be attributed to inadequate dosage of
chorionic gonadotropin. These subjects received a total of 160,000 and
240,000 international units, respectively, which was significantly less than
the 290,000 international units required for the development of gyne-
comastia in the left mammary gland of case 5.
In three of the four subjects (cases 1, 2, and 4) tenderness on pressure
over the areolar area preceded the appearance of a mass in the breast by
approximately one week. Only one subject (case 4), however, complained
of spontaneous pain. Once the gynecomastia developed, it progressed in
size very slowly and ultimately became evident on gross inspection. How-
ever, from the very beginning a clearly defined, indurated, firm disc of
glandular tissue could be palpated in the subareolar area. In no instance did
the breast attain the size seen in the young female at puberty, but in each
there was a soft dome- or cone-shaped swelling approximately twice the
size of the underlying disc of glandular tissue. (It should be noted that the
size of the gynecomastia indicated in Table 2 refers to this disc of tissue.)
Except for tenderness, the nipples and areolae exhibited no changes, and
none of the subjects developed any secretion.
A biopsy specimen was obtained from the involved breast in three of the
subjects (cases 1, 2, and 5). The histological features were essentially the
same in all (Fig. 1) and closely resembled those seen in cases of chorio-
epithelioma,'
" 14 is 19 except for the absence of alveolar development and
secretion. In each instance, the mass was composed of areolar tissue and fat
with a few strands of hyalinized connective tissue separating islands of
actively proliferating, thickened, tortuous, and branching ducts. Immedi-
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ately surrouniding each of the ducts was a mantle of loose, highly cellular
conniective tissue which had a laminated appearance in some areas.
Only in case 5 was it possible to follow the course of the gynecomastia
after gonadotropin therapy had been discontinued. The glands remained
enlarged for a period of two months and then returned to normal. However,
even six months later a small fibrotic nodule could be palpated beneath the
areola on both sides.
No detectable changes occurred in the breasts of the female cirrhotic
control who received 60,000 international units of chorionic gonadotropin.
Conceivably larger doses might have produced hyperplasia, as in Kyle and
O'Donovan's case.' Of interest in this connection are reports of mammary
hyperplasia in women with chorioepitheliomas. %'
Testes. Biopsy specimens obtained before gonadotropin therapy revealed
varying degrees of atrophy of the seminiferous tubules and arrest of
spermatogenesis in every case (Table 3). This was most marked in case 5,
the patient with pituitary deficiency, who also showed considerable thicken-
ing of the basement membrane and peritubular fibrosis (Fig. 2A). The
basement membrane of the tubules was likewise thickened in the cirrhotics,
but to a lesser degree, (Fig. 3A), and there was slight peritubular fibrosis
in the "normal" control (Fig. 4A). As already mentioned, no testicular
tissue was obtained in case 4, and only sections of the epididymal duct
showing varying degrees of epithelial atrophy and degeneration were
demonstrated (Fig. 5A).
The Leydig cells appeared to be normal in number, or only slightly
decreased, in all but the subject with pituitary deficiency, in whom only rare
Leydig cells could be found (Fig. 2A). In contrast, the number of Sertoli
cells was slightly diminished in all cases.
Judging from the findings on subsequent biopsy, the administration of
chorionic gonadotropin produced the following effects on the testis: (a)
more active spermatogenesis in the cirrhotic (case 1), without any detect-
able increase in Leydig or Sertoli cells (Fig. 3B); (b) no significant
change in any of the elements in the patient with pituitary deficiency (Fig.
2B), and (c) a marked increase in the number of Leydig cells in the
"normal" control (Fig. 4B). Chorionic gonadotropin also appeared to
restore the tubular epithelium of the epididymal duct to a normal state in
the patient with congenital ( ?) atrophy or aplasia of the testes (Fig. 5B).
Androgen excretion. As might be expected from previous reports,"
androgen excretion, judged by the results of both the 17-ketosteroid deter-
FIG. 1. Biopsies of hypertrophied mammary glands following chorionic gonadotropin
administration.
A. Case 1 (x 75)
B. Case 2 (x 75)
C. Case 5 (x 75)
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minations and bioassays, was significantly decreased in all the cirrhotics,
including the female, the patients with congenital ( ?) testicular atrophy,
and the patient with pituitary deficiency (Table 4). This did not appear to
be correlated with a decrease in Leydig cells, except in the subjects with
pituitary deficiency and congenital aplasia of the testis. However, estimates
of the number of Leydig cells based on histological examination of biopsy
material do not take into account the volume of the testis, so that they may
not be a reliable index of the amount of functioning interstitial tissue
present.
Serial 17-ketosteroid determinations during the course of gonadotropin
therapy (Table 4) revealed that, despite marked daily variations, there was
a suggestive upward trend in excretion in two of the three male cirrhotics
(cases 1 and 2) and in the female cirrhotic control (case 7). On the other
hand, neither patient with congenital ( ?) testicular atrophy (cases 3 and
4) showed an increase in 17-ketosteroids.
Too few serial bioassays of androgen were carried out to permit any
conclusions, but it is of interest that, whereas in case 1 the 17-ketosteroids
rose from an initial level of 5.1 to a peak of 12.6 mg. per day after 82,000
international units of chorionic gonadotropin, androgen excretion remained
at the low pretreatment level of 0.5 mg. per day. Similarly, in case 2 there
was only a slight rise in androgen excretion, from 0.18 to 0.9 mg. per day,
while the 17-ketosteroids increased from 4.4 to 9.5 mg. per day.
Of special interest was the occurrence of symptoms suggesting androgen
stimulation in three of the subjects receiving gonadotropin. In one of the
cirrhotics (case 2) frequent erections were first noted on the eighth day of
therapy, even before there had been any significant increase in 17-keto-
steroid excretion. Similarly, in case 4, the patient with congenital (?)
atrophy or aplasia of the testes, there was a marked increase in libido and
potency in the ninth week of treatment, and, in addition, an unmistakable
increase in the beard necessitating more frequent shaving. In case 5, the
FIG. 2. Testicular biopsies before and after chorionic gonadotropin administration iti
a subject with pituitary deficiency (case 5).
A. before therapy (x 130)
B. after 510,000 international units (x 130)
FIG. 3. Testicular biopsies before and after chorionic gonadotropin administration in
a subject with Laennec's cirrhosis (case 1).
A. before therapy (x 130)
B. after 68,000 international units (x 130)
FIG. 4. Testicular biopsies before and after chorionic gonadotropin administration in
a "normal control" (case 6).
A. before therapy (x 130)
B. after 240,000 international units (x 130)
FIG. 5. Biopsy of scrotal contents before and after chorionic gonadotropin administra-
tion in a subject with congenital (?) aplasia or atrophy of the testes (case 4).
A. before therapy (x 180)
B. after 195,000 international units (x 180)
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patient with pituitary deficiency, an increased growth of beard was noted at
two weeks, and frequent erections at three weeks.
Estrogen excretion. Bioassay of the urine revealed that two of the male
cirrhotics (cases 1 and 2) were excreting slightly more estrogen than
normal, and during the administration of chorionic gonadotropin the
amount increasedsignificantly (Table4). Chemically determined "estroids,"
on the other hand, remained within the normal range, although in case 2
there was a similar tendency to rise during gonadotropin therapy.
Case 3, the cirrhotic with congenital (?) testicular atrophy, had an
abnormally high "estroid" excretion. During gonadotropin therapy the
level fell transiently and then returned to the initial level. The fall in
estrogen excretion could not be correlated with any change in 17-keto-
steroids (Table 4).
Estrogen excretion was within normal limits in case 4, the patient with
congenital atrophy or aplasia of the testes, but was abnormally low in case
5, the patient with pituitary deficiency (Table 4). Unfortunately, it was
not possible to carry out serial estrogen assays during gonadotropin therapy
in these cases.
The female cirrhotic had an abnormally low level of estrogen excretion,
but this rose to within the normal range during chorionic gonadotropin
administration (Table 4).
Gonadotropin excretion. Both subjects with congenital (?) testicular
atrophy (cases 3 and 4) and the female cirrhotic (case 7) excreted abnor-
mally large amounts of FSH, no doubt reflecting a "castration effect" on
the pituitary (Table 4). On the other hand, as might be expected, the
patient with pituitary deficiency (case 5) excreted very little. In the two
cases of uncomplicated cirrhosis, FSH excretion was low in one (case 1)
and low normal in the other (case 2). Concomitant with the increase in
estrogen excretion noted during gonadotropin therapy in these two cases
there was a fall in FSH excretion. This decrease was not noted during
gonadotropin therapy in case 4, the patient with congenital ( ?) atrophy or
aplasia of the testes; in fact, FSH excretion rose from 70 to > 160 m.u.u.
per day. Unfortunately, parallel studies of estrogen excretion were not car-
ried out in this case, so that it cannot be stated whether there was a recipro-
cal relationship between estrogen and FSH excretion. In view of the well-
recognized fact that estrogen administration will reduce the increased
gonadotropin excretion of eunuchoid men,' it is difficult to reconcile the
high level of urinary gonadotropin in case 3 with the apparent increase in
"estroid" excretion (Table 4), unless it is assumed that the nature of the
compounds from which the latter was derived differed from most of the
natural and synthetic estrogens.
Evidently none of the injected chorionic gonadotropin was excreted in
the urine in cases 1 and 2 who received 2000 international units daily. This
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TABLE 4
DAILY URINARY EXCRETION OF ANDROGEN, ESTROGEN, AND FOLLICLE-STIMULATING GONADOTROPIN
Day of Appear-
gonado- Cumulative ance
tropin dose of of Androgens Estrogen
admin- gonado- gyneco- li-keto- Bio- Bio-
Case istration tropin inastia steroids assay "Estroids" assay F.S.H.
uinits mIg. Img* mcg.t incg. m.U.U.
Normals
Males 10-25 2-10 20-80 0.1-6 1040
Females 6-20 1-10 40-120 10-50
1 -2 0 5.1 0.5 24 4 5
Cirrhosis
2
Cirrhosis
3
Cirrhosis and
Congenital (?)
Testicular
Atrophy
-1 0
1 2,000
6 12,000
8 16,000
13 26,000
15 30,000
20 40,000
22 44,000
27 54,000
34 68,000 *
41 82,000
48 96,000
55 110,000
62 124,000
-1 0
1 2,000
6 12,000
8 16,000
13 26,000
15 30,000
20 40,000
22 44,000
27 54,000
29 58,000 *
34 68,000
41 82,000
48 96,000
55 110,000
62 124,000
76 152,000
-3 0
3 12,000
6 24,000
10 40,000
18 72,000
5.3
4.1
6.2
7.9
1.8
6.8
6.1
3.4
6.8
8.5
12.6
9.1
6.9
5.0
4.4
7.5
6.6
7.2
8.4
7.2
4.9
8.3
7.4
7.1
9.5
6.0
7.1
7.7
9.5
0.3
14
39
14
44
14
7
27
0.5
20
38
0.4 20
3.6
.6 >20
2.9
9.6
8.8
0.2 13 3.9
5.2
56
21
0.7 48 7.2
16
10
0.6 70 11.2
0.9 29 9.6
5.9
2.4
3.7
3.6
5.7
130
34
77
110
<5
18
S
<5
160EXPERIMENTAL PRODUCTION OF GYNECOMASTIA
Day of
gonado-
tropin
admin-
Case istration
4
Congenital (?)
Testicular
Atrophy
5
Pituitary
Deficiency
7
Female
Cirrhotic
-43
-42
14
53
-19
0
43
-2
0
1
6
7
11
12
14
17
23
24
Appear-
Cumulative ance
dose of of
gonado- gyneco- 17-keto- Bio-
tropin mastia steroids assay
untits mg. Mg..*
0
0
30,000
115,000
0
0
172,000
8.8
5.2
7.1
* 5.1
0
0
2,000
12,000
14,000
22,000
24,000
28,000
34,000
46,000
48,000
3.5
5.3
2.3
1.0
2.7
3.3
3.1
2.7
6.0
5.7
11.3
3.4
1.0
Estrogen
Bio-
"Estroids" assay
incg.t mncg.
<3.0
0.4 0.8 <1.4
0.1 21 <1.5
74
16
51
85
* androsterone equivalent (1 mg. = 10 international units of androgen).
t estrone equivalent (1 microgram = 10 international units of estrogen).
is in keeping with the observation of Lloyd and his associates' that it takes
at least 5,000 international units in a single dose to produce an increase in
urinary gonadotropin in non-pregnant females, and the report of Brown
and Bradbury' that it requires daily injections of 10,000 to 20,000 inter-
national units to produce a positive Ascheim-Zondek reaction. It is highly
probable, however, that the increase in urinary gonadotropin in case 4 was
due to the excretion of chorionic gonadotropin, since in this instance the
individual doses were 5,000 units administered thrice weekly.
COMMENT
The amount of chorionic gonadotropin injected in these experiments was
well within the range secreted by the tumor in cases of chorioepithelioma
with spontaneous gynecomastia, and was probably less than average con-
sidering the large amounts usually excreted in the urine.5 For example, in
Hamburger's case"7 the daily urinary excretion of chorionic gonadotropin
was 600,000 international units, and even in a case like Laipply and
Shipley's" in which urine contained only 300 mouse units, the secretion of
F.S.H.
M.u.u.
70
>160
<5
120
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the tumor must have been very much greater considering the fact that only
a fraction of injected chorionic gonadotropin is excreted in the urine.'-',
Similarly, the duration of chorionic gonadotropin administration in these
experiments was well within the range of time it usually takes for gyne-
comastia to develop in patients with chorioepithelioma. Obviously, it is
impossible to determine the age of a tumor precisely, but in the 46 cases
reviewed by Gilbert5 there were 25 in which the date of onset of both
testicular tumor and gynecomastia was given. In these, gynecomastia
appeared on an average of 5.8 months after the presence of the tumor was
recognized, and in 14 of the 25 it appeared in 3 months or less.
If the assumption is correct that the chorionic gonadotropin used in these
experiments was not contaminated significantly by the other hormones
found in human pregnancy urine, it is reasonable to conclude that the
spontaneous gynecomastia of chorioepithelioma, like the experimental vari-
ety described here, is due to chorionic gonadotropin, and not to the other
hormones known to be secreted by chorionic tissue.
Of the possible contaminants found in commercial preparations of chori-
onic gonadotropin derived from human pregnancy urine, only estrogen,
FSH, and prolactin need be considered in connection with possible direct
or indirect mammogenic effects. Estrogen can probably be excluded, since
it is eliminated by the Collip method of extraction. Traces of FSH and pro-
lactin are known to be present in the preparation used, but it is stated that
the amounts are too small to exert any clinical effect.' The relative freedom
of "A.P.L." from contaminating FSH has been confirmed by others.7' In
the present experiments only the slight increase in spermatogenesis ob-
served in case 1 suggested an FSH effect. However, this could have been
due to an increase in androgen, which, under some circumstances, is like-
wise known to promote spermatogenesis,75 or to the secretion of FSH by the
pituitary under the influence of chorionic gonadotropin, as suggested by
Evans and Simpson.76
There is evidence that, quite apart from its ability to stimulate lactation
in the properly prepared gland, prolactin may also induce growth of the
mammary gland.' However, Folley and Malpress,78 who have reviewed this
subject suggest that such growth is probably due to the presence in many
prolactin preparations of contaminating adrenocorticotropin. It is unlikely,
therefore, that prolactin contamination of the chorionic gonadotropin used
in these experiments was responsible for the gynecomastia which was
produced.
There is no evidence that chorionic gonadotropin is capable of eliciting a
growth response in the mammary gland directly, although this possibility has
not been completely excluded. It is more likely, however, that its action is
mediated through the gonads, the pituitary, or the adrenals.
The evidence presented by Geschickter, Lewis, and Hartman'M would
appear to implicate the testis in the mammogenic action of chorionic
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gonadotropin. These investigators found that chorionic gonadotropin in-
duced mammary growth in the male monkey only when the testes were
present, and concluded that this effect was mediated through an increase in
estrogen production related to hyperplasia of the interstitial cells of the
testes. This conclusion, based on the assumption that the interstitial cells
are a source of estrogen and that growth of the mammary duct system is
necessarily due to estrogen, is no longer tenable in the light of more recent
evidence indicating that the Sertoli cells are the sole source of estrogen in
the testis"' and that androgen is also capable of provoking mammary
hyperplasia' ' and gynecomastia.8' It must be assumed, therefore, that, in
the monkey at least, the mammogenic effects of chorionic gonadotropin are
mediated either through the interstitial cells by an increase in androgen
secretion, or through the Sertoli cells by an increase in estrogen. However,
it does not necessarily follow that the same is true in all species. Thus, for
example, Lewis, Turner, and Gomez' were unable to produce growth of
the mammary glands in intact male mice with large doses of chorionic
gonadotropin.
What role the testes played in the present experiments is still uncertain
but the occurrence of gynecomastia in the virtual absence of the testes in
case 4, and the failure to demonstrate interstitial- or Sertoli-cell hyperplasia
in the other subjects who developed gynecomastia strongly suggest that the
mammogenic effects of chorionic gonadotropin were not mediated through
the testes. The rise in 17-ketosteroids, on the other hand, which was ob-
served in at least two of these subjects (cases 1 and 2) might be construed
as evidence of testicular stimulation. However, an adrenal origin for these
steroids cannot be excluded, especially since there was no concomitant
increase in bioassayable androgen, and since there was an equivalent
increase in 17-ketosteroid excretion in the female control. The observations
of Reifenstein and his associates' may be pertinent in this connection. These
investigators described a 27-year-old man with congenital absence of func-
tioning testicular tissue whose 17-ketosteroid excretion was high. This
increased transiently, following the administration of chorionic gonado-
tropin and was interpreted as evidence of compensatory adrenal cortical
hyperplasia. Similarly, the maintenance of secondary sex characteristics'
and the delayed rise in 17-ketosteroid excretion following castration' have
been ascribed to an increase in adrenal cortical activity.
The evidence presented strongly suggests that the mammogenic effects of
chorionic gonadotropin observed in the present experiments were not medi-
ated through the testes, but it cannot be regarded as conclusive, since it was
not possible to preclude with certainty the presence of testicular remnants
in case 4.
The frequency with which hyperplasia of the pituitary is found in cases
of testicular chorioepithelioma`78, 10-18,18,28,24 the development of gyneco-
mastia in some patients with pituitary tumors,8` ' and the evidence compiled
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by Turner and his associates"" implicating the pituitary as the major path-
way for stimuli to mammary growth, point to the pituitary as a possible
site of chorionic gonadotropin action in the production of gynecomastia.
However, it is difficult to reconcile the development of gynecomastia in the
subject with pituitary deficiency (case 5) with this concept, although it
must be conceded that some pituitary tissue probably remained and could
conceivably have been stimulated. More impressive is the experimental evi-
dence that the pituitary has no direct mammogenic action,""" and that,
indeed, in some species its presence is not essential for mammary growth.""
It is highly probable, therefore, that the mammogenic effects of chorionic
gonadotropin are not mediated through the pituitary.
A more convincing case can be made for the participation of the adrenal
cortex in the development of choriogenic gynecomastia. That the adrenal
cortex may, under some conditions, play a role in mammary growth is
indicated by the development of gynecomastia both in association with
adrenal cortical tumors"" and following the administration of adrenal cor-
tical extract' and desoxycorticosterone acetate.' There is also evidence that,
in the hypophysectomized squirrel at least, chorionic gonadotropin is capa-
ble of stimulating the adrenal cortex,"0 and the enlargement of the adrenals
noted in cases of testicular tumor associated with a high gonadotropin out-
put' is suggestive of a similar effect in man. The secretion of colostrum2'"
and the development of alveoli5'10"' in cases of choriogenic gynecomastia
point to a progesterone effect, which is confirmed by the presence of preg-
nandiol in the urine.'-9,' The adrenal cortex is a likely source of this mate-
rial in the male but the presence of progesterone in placental tissue" sug-
gests the chorioepithelioma itself as an alternative source. Support for the
latter possibility is perhaps to be found in the observation that none of the
experimental subjects who received chorionic gonadotropin alone developed
mammary alveoli or secretion.
While the hypothesis that the mammogenic effects of chorionic gonado-
tropin may be mediated through the adrenal cortex is an attractive one, it
must be pointed out that chorionic gonadotropin does not stimulate the
adrenal cortex in all species,' nor do all cases of choriogenic gynecomastia
show adrenal hyperplasia.""' 1,14 15,21. 22 The effects of chorionic gonado-
tropin on the adrenal cortex in man have not been studied very extensively.
Kyle and O'Donovan' administrated 62,000 international units over a
period of 26 days to a young woman with pituitary hypogonadism and
"adrenal androgen deficiency," and observed a slight increase in 17-keto-
steroid excretion, which was accompanied by nodular hyperplasia of the
mammary glands and cornification of the vaginal mucosa. The latter were
interpreted as estrogenic effects indicative of ovarian stimulation, and, for
that reason, it was concluded that the adrenal had not been stimulated and
that the increase in 17-ketosteroids was of ovarian origin. The authors
recognized that inconsistency of an increase in follicular activity following
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the administration of a luteinizing gonadotropin thought to be virtually free
of FSH, and suggested several possible explanations. However, they did
not consider the possibility that the estrogenic effects might be of adrenal
origin. Certainly this could not be excluded since the adrenal cortex is
known to contain estrogenic compounds? and to be capable of secreting
them under some conditions.'
Recently Landau and his associates? studied the metabolic effects of
chorionic gonadotropin in normal and eunuchoid men, and presented evi-
dence to show that these effects were mediated through the testes. How-
ever, they recognized that minimal adrenal influences could not be excluded.
Moreover, the possibility that these might be enhanced by more prolonged
and intense gonadotropin stimulation must be considered, since these
authors used relatively small doses, 14,000 international units in six days,
an amount far less than that used in the present experiments or excreted
in the average case of chorioepithelioma.
Tentatively, the adrenal cortex appears to be the most likely site of action
of chorionic gonadotropin in producing gynecomastia. However, more
direct proof of this hypothesis is still needed. A study of the effects of large
doses of chorionic gonadotropin in castrates and in adrenalectomized males
might serve to exclude the testis and establish the adrenal cortex as the
pathway through which chorionic gonadotropin exerts its mammogenic
effect. Unfortunately, it has not been possible for us to carry out such
studies because of lack of suitable experimental subjects, but it is hoped
that others who have access to such subjects may be able to do so.
SUMMARY
Large doses of chorionic gonadotropin, derived from human pregnancy
urine and given over a relatively long period, produced gynecomastia in
two cirrhotics, in a subject with congenital atrophy or aplasia of the testes,
and in a patient with pituitary deficiency. In the two subjects studied
serially there was a concomitant increase in 17-ketosteroid and estrogen
excretion, which was also observed in a female cirrhotic control. However,
there was little or no increase in androgen excretion by bioassay, and in
none of the subjects with gynecomastia was there histological evidence of
interstitial- or Sertoli-cell hyperplasia in the testis.
On the basis of these observations and a review of the pertinent literature
the following tentative conclusions have been drawn:
(a) The gynecomastia seen in association with chorioepitheliomas is
probably related to the secretion of chorionic gonadotropin and not to any
of the other hormones known to occur in such tissue.
(b) The colostrum-like secretion and the mammary alveolar develop-
ment seen in some cases are probably due to progesterone, derived either
from the tumor itself or from the adrenal cortex.
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(c) The effect of chorionic gonadotropin on the male mammary gland is
not a direct one, but is probably mediated through.the pituitary, testes, or
adrenal.
(d) The adrenal cortex is a likely site for this action, but further studies
are needed to exclude other possibilities.
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